Japanese pharma major Eisai (TYO: 4523) and US partner Arena Pharmaceuticals (Nasdaq: ARNA) have received US Food and Drug Administration approval of the New Drug Application for obesity drug Belviq XR (lorcaserin HCl) CIV extended-release 20mg tablets.
News of the approval saw Eisai’s shares increase over 4% to 6,224 yen, while Arena moved 2.4% higher to $1.70.
The new formulation of lorcaserin will offer patients a once-a-day dosing option that may help them achieve and maintain weight loss. Belviq XR is expected to be available in the fall of 2016. In connection with the approval, Arena will receive a $10 million milestone payment from Eisai.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze